As FDA regulatory expectations evolve, distinguishing between SIUU and unsolicited scientific requests is essential.
This quick‑reference chart highlights the key differences between these two regulatory pathways (evidence standards, communication pathways, documentation requirements, etc.) so field teams can conduct scientific exchange confidently and compliantly.
View the full side-by-side breakdown.
Download NowAuthor
Beth brings over 16 years of Medical Affairs experience, during which she has led Medical Strategy teams as well as Field Medical Affairs teams in support of over 10 launches in various therapeutic areas.
Amber Svardal, MSN, RN, OCN
Director, Medical Excellence and Sr. MSL at Precigen, contracted exclusively by EVERSANA
Amber Svardal, RN, MSN, OCN, is a Senior Medical Science Liaison at Precigen currently supporting their rare disease program. She brings over six years of oncology-focused pharmaceutical experience in Medical Affairs, supported by more…